Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 29

1.

A Sendai virus recombinant vaccine expressing a gene for truncated human metapneumovirus (hMPV) fusion protein protects cotton rats from hMPV challenge.

Russell CJ, Jones BG, Sealy RE, Surman SL, Mason JN, Hayden RT, Tripp RA, Takimoto T, Hurwitz JL.

Virology. 2017 Sep;509:60-66. doi: 10.1016/j.virol.2017.05.021. Epub 2017 Jun 9.

PMID:
28605636
2.

Low Retinol-Binding Protein and Vitamin D Levels Are Associated with Severe Outcomes in Children Hospitalized with Lower Respiratory Tract Infection and Respiratory Syncytial Virus or Human Metapneumovirus Detection.

Hurwitz JL, Jones BG, Penkert RR, Gansebom S, Sun Y, Tang L, Bramley AM, Jain S, McCullers JA, Arnold SR.

J Pediatr. 2017 Aug;187:323-327. doi: 10.1016/j.jpeds.2017.04.061. Epub 2017 May 31.

PMID:
28578159
3.

A Respiratory Syncytial Virus Vaccine Vectored by a Stable Chimeric and Replication-Deficient Sendai Virus Protects Mice without Inducing Enhanced Disease.

Wiegand MA, Gori-Savellini G, Gandolfo C, Papa G, Kaufmann C, Felder E, Ginori A, Disanto MG, Spina D, Cusi MG.

J Virol. 2017 Apr 28;91(10). pii: e02298-16. doi: 10.1128/JVI.02298-16. Print 2017 May 15.

4.

Sendai virus as a backbone for vaccines against RSV and other human paramyxoviruses.

Russell CJ, Hurwitz JL.

Expert Rev Vaccines. 2016;15(2):189-200. doi: 10.1586/14760584.2016.1114418. Epub 2015 Dec 9. Review.

6.

Safety and immunogenicity of an intranasal Sendai virus-based human parainfluenza virus type 1 vaccine in 3- to 6-year-old children.

Adderson E, Branum K, Sealy RE, Jones BG, Surman SL, Penkert R, Freiden P, Slobod KS, Gaur AH, Hayden RT, Allison K, Howlett N, Utech J, Allay J, Knight J, Sleep S, Meagher MM, Russell CJ, Portner A, Hurwitz JL.

Clin Vaccine Immunol. 2015 Mar;22(3):298-303. doi: 10.1128/CVI.00618-14. Epub 2014 Dec 31.

7.

Sendai virus recombinant vaccine expressing a secreted, unconstrained respiratory syncytial virus fusion protein protects against RSV in cotton rats.

Zhan X, Slobod KS, Jones BG, Sealy RE, Takimoto T, Boyd K, Surman S, Russell CJ, Portner A, Hurwitz JL.

Int Immunol. 2015 May;27(5):229-36. doi: 10.1093/intimm/dxu107. Epub 2014 Dec 4.

8.

Mucosal vaccines against respiratory syncytial virus.

Yang K, Varga SM.

Curr Opin Virol. 2014 Jun;6:78-84. doi: 10.1016/j.coviro.2014.03.009. Epub 2014 Apr 29. Review.

9.

Sendai virus-based RSV vaccine protects against RSV challenge in an in vivo maternal antibody model.

Jones BG, Sealy RE, Surman SL, Portner A, Russell CJ, Slobod KS, Dormitzer PR, DeVincenzo J, Hurwitz JL.

Vaccine. 2014 May 30;32(26):3264-73. doi: 10.1016/j.vaccine.2014.03.088. Epub 2014 Apr 14.

10.

A respiratory syncytial virus (RSV) vaccine based on parainfluenza virus 5 (PIV5).

Phan SI, Chen Z, Xu P, Li Z, Gao X, Foster SL, Teng MN, Tripp RA, Sakamoto K, He B.

Vaccine. 2014 May 23;32(25):3050-7. doi: 10.1016/j.vaccine.2014.03.049. Epub 2014 Apr 8.

11.

Oral retinyl palmitate or retinoic acid corrects mucosal IgA responses toward an intranasal influenza virus vaccine in vitamin A deficient mice.

Surman SL, Jones BG, Sealy RE, Rudraraju R, Hurwitz JL.

Vaccine. 2014 May 7;32(22):2521-4. doi: 10.1016/j.vaccine.2014.03.025. Epub 2014 Mar 21.

12.

Characterization of innate responses to influenza virus infection in a novel lung type I epithelial cell model.

Rosenberger CM, Podyminogin RL, Askovich PS, Navarro G, Kaiser SM, Sanders CJ, McClaren JL, Tam VC, Dash P, Noonan JG, Jones BG, Surman SL, Peschon JJ, Diercks AH, Hurwitz JL, Doherty PC, Thomas PG, Aderem A.

J Gen Virol. 2014 Feb;95(Pt 2):350-62. doi: 10.1099/vir.0.058438-0. Epub 2013 Nov 16.

13.

Influence of antigen insertion site and vector dose on immunogenicity and protective capacity in Sendai virus-based human parainfluenza virus type 3 vaccines.

Mason JN, Elbahesh H, Russell CJ.

J Virol. 2013 May;87(10):5959-69. doi: 10.1128/JVI.00227-13. Epub 2013 Mar 20.

14.

Respiratory syncytial virus: current progress in vaccine development.

Rudraraju R, Jones BG, Sealy R, Surman SL, Hurwitz JL.

Viruses. 2013 Feb 5;5(2):577-94. doi: 10.3390/v5020577. Review.

15.

Reduced frequencies and heightened CD103 expression among virus-induced CD8(+) T cells in the respiratory tract airways of vitamin A-deficient mice.

Rudraraju R, Surman SL, Jones BG, Sealy R, Woodland DL, Hurwitz JL.

Clin Vaccine Immunol. 2012 May;19(5):757-65. doi: 10.1128/CVI.05576-11. Epub 2012 Mar 7.

16.

Targeting RSV with vaccines and small molecule drugs.

Costello HM, Ray WC, Chaiwatpongsakorn S, Peeples ME.

Infect Disord Drug Targets. 2012 Apr;12(2):110-28. Review.

17.

Sendai virus-based RSV vaccine protects African green monkeys from RSV infection.

Jones BG, Sealy RE, Rudraraju R, Traina-Dorge VL, Finneyfrock B, Cook A, Takimoto T, Portner A, Hurwitz JL.

Vaccine. 2012 Jan 20;30(5):959-68. doi: 10.1016/j.vaccine.2011.11.046. Epub 2011 Nov 23. Erratum in: Vaccine. 2012 Nov 6;30(48):6955. Dosage error in article text.

18.

Respiratory syncytial virus vaccine development.

Hurwitz JL.

Expert Rev Vaccines. 2011 Oct;10(10):1415-33. doi: 10.1586/erv.11.120. Review.

19.

Viruslike particle vaccine induces protection against respiratory syncytial virus infection in mice.

Quan FS, Kim Y, Lee S, Yi H, Kang SM, Bozja J, Moore ML, Compans RW.

J Infect Dis. 2011 Oct 1;204(7):987-95. doi: 10.1093/infdis/jir474. Erratum in: J Infect Dis. 2012 Feb;205(3):520.

20.

Illumination of parainfluenza virus infection and transmission in living animals reveals a tissue-specific dichotomy.

Burke CW, Mason JN, Surman SL, Jones BG, Dalloneau E, Hurwitz JL, Russell CJ.

PLoS Pathog. 2011 Jul;7(7):e1002134. doi: 10.1371/journal.ppat.1002134. Epub 2011 Jul 7.

Supplemental Content

Support Center